English

Sienna Biopharmaceuticals, Inc.

EDGAR

SNNA Quarterly report (10-Q) · filed 2019-11-12

12 filing records in this dataset, filed from 2017-07-03 to 2019-11-12. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2018 Q4 · USD

Exact inputs and evidence

Revenue: 0 USD Source
Revenue: 0 USD Source

Operating cash flow

-15.6 million USD

2018 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -61693000 USD Source
Operating Cash Flow: -46094000 USD Source

Free cash flow

-15.6 million USD

2018 Q4 · USD

Exact inputs and evidence

Operating Cash Flow: -61693000 USD Source
Operating Cash Flow: -46094000 USD Source
Capital Expenditure: 39000 USD Source
Capital Expenditure: 33000 USD Source

Cash and cash equivalents: 11.3 million USD 2019-09-30 Source
Exact value

11332000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 30.8 million shares 2019-09-30 Source
Exact value

30765000 shares

Reported share-count change

48.22% · 10 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

20756000 shares · 2018-09-30· Source
30765000 shares · 2019-09-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

0 USD

2018-01-01 – 2018-12-31

Exact inputs and evidence

Revenue: 0 USD · 2018-01-01 – 2018-03-31 Source
Revenue: 0 USD · 2018-01-01 – 2018-06-30 Source
Revenue: 0 USD · 2018-01-01 – 2018-03-31 Source
Revenue: 0 USD · 2018-01-01 – 2018-09-30 Source
Revenue: 0 USD · 2018-01-01 – 2018-06-30 Source
Revenue: 0 USD · 2018-01-01 – 2018-12-31 Source
Revenue: 0 USD · 2018-01-01 – 2018-09-30 Source

Net income

-48 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Net income: -19335000 USD · 2018-10-01 – 2018-12-31 Source
Net income: -16382000 USD · 2019-01-01 – 2019-03-31 Source
Net income: -8264000 USD · 2019-04-01 – 2019-06-30 Source
Net income: -3970000 USD · 2019-07-01 – 2019-09-30 Source

Operating cash flow

-54.6 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Operating cash flow: -61693000 USD · 2018-01-01 – 2018-12-31 Source
Operating cash flow: -46094000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -12769000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -21186000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -12769000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -39030000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -21186000 USD · 2019-01-01 – 2019-06-30 Source

Capital expenditure

10 thousand USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Capital expenditure: 39000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 33000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-06-30 Source

Free cash flow

-54.6 million USD

2018-10-01 – 2019-09-30

Exact inputs and evidence

Operating cash flow: -61693000 USD · 2018-01-01 – 2018-12-31 Source
Operating cash flow: -46094000 USD · 2018-01-01 – 2018-09-30 Source
Operating cash flow: -12769000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -21186000 USD · 2019-01-01 – 2019-06-30 Source
Operating cash flow: -12769000 USD · 2019-01-01 – 2019-03-31 Source
Operating cash flow: -39030000 USD · 2019-01-01 – 2019-09-30 Source
Operating cash flow: -21186000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 39000 USD · 2018-01-01 – 2018-12-31 Source
Capital expenditure: 33000 USD · 2018-01-01 – 2018-09-30 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-06-30 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-03-31 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-09-30 Source
Capital expenditure: 4000 USD · 2019-01-01 – 2019-06-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2019-11-12.

Financial data available through: 2018-12-31.

Coverage by financial measure

Revenue: 1 of 11 periods available· newest 2018-12-31
Operating income: 4 of 11 periods available· newest 2018-12-31
Net income: 4 of 11 periods available· newest 2018-12-31
Operating cash flow: 4 of 11 periods available· newest 2018-12-31
Capital expenditure: 4 of 11 periods available· newest 2018-12-31
Total assets: 1 of 11 periods available· newest 2018-12-31
Total liabilities: 1 of 11 periods available· newest 2018-12-31
Current assets: 1 of 11 periods available· newest 2018-12-31
Current liabilities: 1 of 11 periods available· newest 2018-12-31
Cash and cash equivalents: 1 of 11 periods available· newest 2018-12-31
long term debt: No compatible figures in this window
Shares outstanding: 1 of 11 periods available· newest 2018-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−USD 22.93 million

Prior period

−USD 50.55 million

2017-01-01 – 2017-12-31
Current period

−USD 73.47 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-73471000 − -50545000 = -22926000 USD

-50545000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-73471000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Sienna Biopharmaceuticals, Inc. · 2018-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Year-over-year change in Net income: -22926000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -73471000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#403138 Filing: 000119312519074162 Input fundies:NetIncome: -50545000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#111619 Filing: 000119312519074162
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 20.68 million

Prior period

−USD 41.01 million

2017-01-01 – 2017-12-31
Current period

−USD 61.69 million

2018-01-01 – 2018-12-31

Exact inputs and evidence

-61693000 − -41012000 = -20681000 USD

-41012000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
-61693000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Sienna Biopharmaceuticals, Inc. · 2018-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Year-over-year change in Operating cash flow: -20681000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -61693000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#402869 Filing: 000119312519074162 Input fundies:OperatingCashFlow: -41012000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#111350 Filing: 000119312519074162
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-85.8%

Prior period

USD 274,000

2017-01-01 – 2017-12-31
Current period

USD 39,000

2018-01-01 – 2018-12-31

Exact inputs and evidence

39000 − 274000 = -235000 USD

274000 USD · 2017-01-01 – 2017-12-31
Inspect prior input Prior source
39000 USD · 2018-01-01 – 2018-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Sienna Biopharmaceuticals, Inc. · 2018-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Year-over-year change in Capital expenditure: -235000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 39000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#411451 Filing: 000119312519074162 Input fundies:CapitalExpenditure: 274000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#113929 Filing: 000119312519074162
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2018-01-01 – 2018-12-31

Revenue USD 0
Operating costs Derived USD 76.5 million
Operating income −USD 76.5 million
Tax, interest and other Derived −USD 3.03 million
Net income −USD 73.47 million

Cash

Operating cash flow −USD 61.69 million
Capital expenditure USD 39,000
Free cash flow Derived −USD 61.73 million

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2018 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2018 2018-01-01 – 2018-12-31	0	76498000 Derived	-76498000	-3027000 Derived	-73471000	-61732000 Derived	Source 2018-01-01 – 2018-12-31: 0 USD Inspect Revenue Open source 2018-01-01 – 2018-12-31: -76498000 USD Inspect Operating Income Open source 2018-01-01 – 2018-12-31: -73471000 USD Inspect Net Income Open source 2018-01-01 – 2018-12-31: -61693000 USD Inspect Operating Cash Flow Open source 2018-01-01 – 2018-12-31: 39000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 0 2018

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Revenue	0	Revenue: 0 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

Not enough comparable data to show this history.

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Year over year	No prior comparable period	Revenue: 0 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Operating margin	Not reported	Operating Income: -76498000 Open source Revenue: 0 Open source
20182018-12-31	Net margin	Not reported	Net Income: -73471000 Open source Revenue: 0 Open source
20182018-12-31	Free cash flow margin	Not reported	Revenue: 0 Open source Operating Cash Flow: -61693000 Open source Capital Expenditure: 39000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -61.7M 2018

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Operating cash flow	-61693000	Operating Cash Flow: -61693000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -61.7M 2018

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20182018-12-31	Free cash flow	-61732000	Operating Cash Flow: -61693000 Open source Capital Expenditure: 39000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

75.2% 2018

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Liabilities / assets	75.2%	Total Liabilities: 80725000 Open source Total Assets: 107306000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.07× 2018

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20182018-12-31	Current assets / current liabilities	2.07×	Current Assets: 50412000 Open source Current Liabilities: 24349000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2015 2015-01-01 – 2015-12-31	−USD 11.29 million Exact value Exact value: -11294000 USD 2015-01-01 – 2015-12-31: -11294000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sienna Biopharmaceuticals, Inc. · 2015-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Net Income: -11294000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -11294000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312518084145/snna-20171231.xml#99428 Filing: 000119312518084145 The citation records this snapshot. The page link may show a newer release later.	−USD 9.98 million Exact value Exact value: -9979000 USD 2015-01-01 – 2015-12-31: -9979000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sienna Biopharmaceuticals, Inc. · 2015-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Operating Cash Flow: -9979000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -9979000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312518084145/snna-20171231.xml#98595 Filing: 000119312518084145 The citation records this snapshot. The page link may show a newer release later.	USD 88,000 Exact value Exact value: 88000 USD 2015-01-01 – 2015-12-31: 88000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sienna Biopharmaceuticals, Inc. · 2015-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Capital Expenditure: 88000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 88000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312518084145/snna-20171231.xml#100577 Filing: 000119312518084145 The citation records this snapshot. The page link may show a newer release later.	−USD 10.07 million Calculation and evidence -9979000 − 88000 USD Exact free cash flow: -10067000 USD 2015-01-01 – 2015-12-31: -9979000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 88000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sienna Biopharmaceuticals, Inc. · 2015-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Free cash flow: -10067000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -9979000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312518084145/snna-20171231.xml#98595 Filing: 000119312518084145 Input fundies:CapitalExpenditure: 88000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312518084145/snna-20171231.xml#100577 Filing: 000119312518084145 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 21.16 million Exact value Exact value: -21162000 USD 2016-01-01 – 2016-12-31: -21162000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sienna Biopharmaceuticals, Inc. · 2016-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Net Income: -21162000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -21162000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#803135 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.	−USD 17.61 million Exact value Exact value: -17609000 USD 2016-01-01 – 2016-12-31: -17609000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sienna Biopharmaceuticals, Inc. · 2016-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Operating Cash Flow: -17609000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -17609000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#802866 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.	USD 238,000 Exact value Exact value: 238000 USD 2016-01-01 – 2016-12-31: 238000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sienna Biopharmaceuticals, Inc. · 2016-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Capital Expenditure: 238000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 238000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#805353 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.	−USD 17.85 million Calculation and evidence -17609000 − 238000 USD Exact free cash flow: -17847000 USD 2016-01-01 – 2016-12-31: -17609000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 238000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sienna Biopharmaceuticals, Inc. · 2016-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Free cash flow: -17847000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -17609000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#802866 Filing: 000119312519074162 Input fundies:CapitalExpenditure: 238000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#805353 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−USD 50.55 million Exact value Exact value: -50545000 USD 2017-01-01 – 2017-12-31: -50545000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sienna Biopharmaceuticals, Inc. · 2017-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Net Income: -50545000 USD Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:NetIncome: -50545000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#111619 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.	−USD 41.01 million Exact value Exact value: -41012000 USD 2017-01-01 – 2017-12-31: -41012000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sienna Biopharmaceuticals, Inc. · 2017-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Operating Cash Flow: -41012000 USD Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -41012000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#111350 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.	USD 274,000 Exact value Exact value: 274000 USD 2017-01-01 – 2017-12-31: 274000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sienna Biopharmaceuticals, Inc. · 2017-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Capital Expenditure: 274000 USD Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 274000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#113929 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.	−USD 41.29 million Calculation and evidence -41012000 − 274000 USD Exact free cash flow: -41286000 USD 2017-01-01 – 2017-12-31: -41012000 USD · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 274000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sienna Biopharmaceuticals, Inc. · 2017-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Free cash flow: -41286000 USD Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -41012000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#111350 Filing: 000119312519074162 Input fundies:CapitalExpenditure: 274000 USD (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#113929 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	−USD 73.47 million Exact value Exact value: -73471000 USD 2018-01-01 – 2018-12-31: -73471000 USD Inspect Net Income Open source Share or cite Citation for Net Income · Sienna Biopharmaceuticals, Inc. · 2018-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Net Income: -73471000 USD Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:NetIncome: -73471000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#403138 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.	−USD 61.69 million Exact value Exact value: -61693000 USD 2018-01-01 – 2018-12-31: -61693000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Sienna Biopharmaceuticals, Inc. · 2018-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Operating Cash Flow: -61693000 USD Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -61693000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#402869 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.	USD 39,000 Exact value Exact value: 39000 USD 2018-01-01 – 2018-12-31: 39000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Sienna Biopharmaceuticals, Inc. · 2018-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Capital Expenditure: 39000 USD Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 39000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#411451 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.	−USD 61.73 million Calculation and evidence -61693000 − 39000 USD Exact free cash flow: -61732000 USD 2018-01-01 – 2018-12-31: -61693000 USD · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 39000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Sienna Biopharmaceuticals, Inc. · 2018-12-31 Sienna Biopharmaceuticals, Inc. (edgar:1656328) Free cash flow: -61732000 USD Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T17:15:40Z Snapshot: 1636ff16f8d542b9d5511d46e98014b58ce935497881749ec74dc9c65e593eb2 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1656328?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -61693000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#402869 Filing: 000119312519074162 Input fundies:CapitalExpenditure: 39000 USD (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1656328/000119312519074162/snna-20181231.xml#411451 Filing: 000119312519074162 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

12 filings · 694 latest values · 694 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001656328, 1656328, SNNA, edgar:1656328

Also known as Sienna Biopharmaceuticals, Inc., Sienna Labs, Inc.

Sienna Biopharmaceuticals, Inc.

Latest quarter

Revenue

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2018 2018-01-01 – 2018-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation